000142027 001__ 142027
000142027 005__ 20240229105139.0
000142027 0247_ $$2doi$$a10.1097/CCO.0000000000000478
000142027 0247_ $$2pmid$$apmid:30102604
000142027 0247_ $$2ISSN$$a1040-8738
000142027 0247_ $$2ISSN$$a1040-8746
000142027 0247_ $$2ISSN$$a1531-7021
000142027 0247_ $$2ISSN$$a1531-703X
000142027 0247_ $$2altmetric$$aaltmetric:46501673
000142027 037__ $$aDKFZ-2018-02257
000142027 041__ $$aeng
000142027 082__ $$a610
000142027 1001_ $$0P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c$$aFriedrich, Mirco$$b0$$eFirst author$$udkfz
000142027 245__ $$aPerspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
000142027 260__ $$a[S.l.]$$bOvid$$c2018
000142027 3367_ $$2DRIVER$$aarticle
000142027 3367_ $$2DataCite$$aOutput Types/Journal article
000142027 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659697606_13807$$xReview Article
000142027 3367_ $$2BibTeX$$aARTICLE
000142027 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142027 3367_ $$00$$2EndNote$$aJournal Article
000142027 520__ $$aThe present review introduces recent progress in eliciting the role of mutant isocitrate dehydrogenase (IDH) in gliomas, especially regarding its mode of action as a modulator of antitumor immune response, and provides rationales for targeting mutant IDH in glioma immunotherapy. Both the development of small molecule inhibitors repressing the enzymatic activity of mutant IDH and novel, mechanism-led combination immunotherapies are discussed.Since the discovery of highly frequent IDH mutations in low-grade gliomas and nonsolid malignancies, its tumor cell-intrinsic effects have been intensively investigated. Tumor cells expressing mutant IDH display profound alterations of redox control capacity, phospholipid profile, and ATP supply. Recent findings suggest that IDH mutations - via intricate, yet druggable pathways - cause immunological alterations, highlighting the importance of oncogenic drivers as modulators of antitumor immunity and targets for immunotherapy.Mutant IDH is not only a disease-defining biomarker and oncogenic driver in glioma, but is also a neoantigen and a regulator of glioma immune evasion. Effective and specific strategies targeting the immunomodulatory properties of mutant IDH may complement current (immuno-)therapeutic strategies and approved antiglioma treatments to improve outcome.
000142027 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142027 588__ $$aDataset connected to CrossRef, PubMed,
000142027 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b1$$udkfz
000142027 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b2$$udkfz
000142027 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b3$$eLast author$$udkfz
000142027 773__ $$0PERI:(DE-600)2026986-9$$a10.1097/CCO.0000000000000478$$gVol. 30, no. 6, p. 1 -$$n6$$p368-374$$tCurrent opinion in oncology$$v30$$x1040-8746$$y2018
000142027 909CO $$ooai:inrepo02.dkfz.de:142027$$pVDB
000142027 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142027 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142027 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142027 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142027 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142027 9141_ $$y2018
000142027 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000142027 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142027 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142027 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142027 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142027 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN ONCOL : 2017
000142027 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142027 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142027 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142027 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142027 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142027 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142027 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142027 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000142027 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000142027 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000142027 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000142027 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x1
000142027 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000142027 980__ $$ajournal
000142027 980__ $$aVDB
000142027 980__ $$aI:(DE-He78)G160-20160331
000142027 980__ $$aI:(DE-He78)G370-20160331
000142027 980__ $$aI:(DE-He78)L101-20160331
000142027 980__ $$aUNRESTRICTED